Carlos Rubio Terrés


Carlos Rubio Terrés is Director of HEALTH VALUE, Health Economics & Research of Outcomes Consulting, in Madrid, Spain. He holds a master’s degree in Pharmacology from the School of Medicine of University of Barcelona, a degree in Pharmacoeconomics from the National School of Public Health in Madrid, and a bachelor´s degree in Biological sciences from the University Autónoma of Madrid, Spain. Over the past three decades he has held various positions in the fields of drugs evaluation and pharmacoeconomics, including Technical advisor at the Pharmacobiology National Centre, Instituto de Salud Carlos III, and the Drug Evaluation Unit, Ministry of Health, Madrid, Spain. He has also served as a member of the Committee for Proprietary Medicinal Products (CPMP) on behalf of the Spanish Ministry of Health, in Brussels. He holds various positions (Regulatory Affairs Manager, Scientific Services Manager, Pharmacoeconomics Manager) in a number of pharmaceutical companies (Lederle, Wyeth, Aventis).


Carlos Rubio Terrés is currently a reviewer for numerous medical and economic journals, including the British Medical Journal, and a member of the Editorial Committee of Pharmacoeconomics Spanish Research Articles (Adis International) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Speaker´s Bureau. He has published 246 articles in peer-reviewed journals and book chapters on pharmacoeconomics, meta-analysis, decision analysis, regulatory affairs, clinical trials, statistical design of health research, pharmacology and toxicology, and numerous communications and posters at conferences.

 


 

C/ Virgen de Aránzazu, 21 5º B • 28034 • Madrid • Phone: +34 917 293 503 • Email: crubioterres@healthvalue.org www.healthvalue.org
Copyright © 2012 HEALTH VALUE • Terms and conditions of usePrivacy Policy
Diseño Web

 
Site Map      
SERVICES
WHY CHOOSE HEALTH VALUE?
CLIENTS
EXPERIENCE
PUBLICATIONS AND REPORTS
CONTACTS
HOME

Copyright 2012 All right reserved: Pharmacoeconomics, health economics, health outcomes research, cost-effectiveness, disease burden, budget impact, systematic reviews, meta-analysis, pharmacoeconomic courses, therapeutic value and pharmacoeconomics reports, price and reimbursement negociation, scientific writing